UnityPoint Health - Des Moines

NCI MATCH

EAY131: Screening for Treatment Assignment Based on Genetic Testing (Molecular Analysis for Therapy Choice [MATCH])

MATCH Treatment Protocols

EAY131-A: Phase II Trial of Afatinib in Patients with Solid Tumors (other than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, that have Activating Mutations of EGFR and Have Progressed After Standard Treatment

EAY131-B: Phase II Study of Afatinib in Patients with Tumors with HER2 Activating Mutations

EAY131-C1: Crizotinib in Patients with Tumors with MET Amplification

EAY131-C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion

EAY131-E: AZD9291 in Patients with Tumors having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR

EAY131-F: Crizotinib in Patients with Tumors (other than adenocarcinoma of lung or ALCL) with ALK Translocations

EAY131-G: Phase II Study of Crizotinib in Patients with ROS1 Translocations (other than patients with non-small cell lung cancer)

EAY131-H: Phase II Study of Dabrafenib and Trametinib in Patients with Tumors with BRAF V600E or V600K mutations (excluding melanoma and thyroid cancer)

EAY131-I: GDC_0032 (taselisib) in Patients with Tumors (other than breast cancer) with PIK3CA Mutation but without KRAS Mutation or PTEN Loss

EAY131-J: Trastuzumab and Pertuzumab (HP) in Patients with Non-Breast, Non-Gastric / GEJ Cancers with HER2 Amplification

EAY131-L: Phase II Study of MLN-0128 (TAK-228) in Patients with Tumors with mTOR Mutations

EAY131-M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations

EAY131-N: Phase II Study of PI3K Beta Specific Inhibitor, GSK2636771, in Patients with Tumors with PTEN Mutation or Deletion, with PTEN Expression on IHC

EAY131-P: Phase II Study of PI3K Beta Specific Inhibitor, GSK2636771, in Patients with Tumors with PTEN Loss by IHC

EAY131-Q: Ado-trastuzumab Emtansine in Patients with Tumors having HER2 Amplification (Except Breast and Gastric / Gastro-Esophageal Junction (GEJ) Adenocarcinomas)

EAY131-R: Phase II Study of Trametinib in Patients with BRAF Fusions, or with Non-V600E, Non V600K BRAF Mutations

EAY131-S1: Phase II Study of Trametinib in Patients with Tumors with NF1 Mutations

EAY131-S2: Phase II Study of Trametinib in Patients with Tumors with GNAQ or GNA11 Mutations

EAY131-T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations

EAY131-U: VS-6063 (defactinib) in Patients with Tumors with NF2 Loss

EAY131-V:
Phase II Study of Sunitinib in Patients with Tumors with c-Kit Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)

EAY131-W: Phase II Study of AZD4547 in Patients with Tumors with Aberrations with FGFR Pathway

EAY131-X: Phase II Study of Dasatinib in Patients with Tumors with DDR2 Mutations

EAY131-Y: AZD5363 in Patients with Tumors with AKT Mutations

EAY131-Z1A:
Binimetinib in Patients with Tumors (Other than Melanoma) with NRAS Mutations

EAY131-Z1B: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CCND1, 2,3 Amplification and Rb Protein Expression by IHC

EAY131-Z1C: Phase II Study of Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification and Rb Protein Expression by IHC

EAY131-Z1D: Nivolumab in Patients with Tumors with Mismatch Repair Deficiency (Excluding Colorectal Cancer)

EAY131-Z1E: LOX-101 in Patient with Tumors with NTRK Fusions

EAY131-Z1I: Phase II Study of AZD1775 in Patients with Tumors Containing BRCA1 or BRCA2 Mutations

DART

S1609: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors